Healthcare · VIJAYA
Diagnostics
from 1,351 today
Vijaya Diagnostic's Q1FY27 result was ahead of expectations, with revenue growing 22.8% YoY, driven by strong network expansion and balanced growth across regions. We upgrade to BUY with a higher target price of INR 1,600.
Vijaya Diagnostic delivered an all-round beat in Q1FY27 with revenue/EBITDA/PAT surpassing consensus by 3%/7%/11%. We forecast revenue/PAT CAGR of 22%/33% over FY26–28E and retain 'BUY' with a TP of INR1,555.
Vijaya delivered a broadly in-line 1QFY27, with revenue growing 23% YoY to INR 2.3bn, led by test volume growth and improved realizations. We maintain our positive view supported by continued market share gains, strong traction in newly established hubs, and sustained network expansion, and maintain our BUY rating with a revised target price of INR 1,570.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
